BGM Group (BGM) vs vTv Therapeutics (VTVT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
vTv Therapeutics (VTVT) has outperformed BGM Group (BGM) over the past year, gaining 36.2% versus a loss of 96.3%. Over five years, VTVT leads with a -47.0% price change compared with -98.2% for BGM. BGM Group is the larger company by market cap ($143.6 million vs $123.3 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BGM | VTVT |
|---|---|---|
| Share price | $10.75 | $31.18 |
| Market cap | $143.56M | $123.28M |
| 1-day change | +10.94% | +3.66% |
| YTD return | -90.29% | -22.03% |
| 1-year return | -96.31% | +36.22% |
| 5-year return | -98.19% | -46.97% |
| EPS (TTM) | $-4.80 | $-0.72 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $303.00 | $44.00 |
| 52-week low | $6.45 | $19.50 |
| Distance from 52-week high | -96.45% | -29.14% |
| Analyst consensus | — | strong_buy |
| Avg. price target upside | — | +75.47% |
| Average volume | 6.11K | 68.34K |
| Shares outstanding | 12.69M | 3.95M |
| Employees | — | 26 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- VTVT has outperformed BGM by 132.5 percentage points over the past year.
About BGM Group
BGM stock →BGM Group Ltd., through its subsidiaries, operates as a pharmaceutical and chemical company in China. The company operates through Diversified Pharmaceutical and Allied Products; AI Solution; and Insurance Business segments.
Health Care · Biotechnology: Pharmaceutical Preparations
About vTv Therapeutics
VTVT stock →vTv Therapeutics Inc., a late-stage biopharmaceutical company, focuses on developing oral small molecule drug candidates intended to treat people living with diabetes and other chronic diseases. Its lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial to treat type 1 diabetes.
Health Care · Biotechnology: Pharmaceutical Preparations · 26 employees
BGM vs VTVT FAQ
Which is bigger, BGM Group or vTv Therapeutics?
BGM Group (BGM) is larger, with a market capitalization of $143.56M compared with $123.28M for vTv Therapeutics (VTVT).
Which stock has performed better over the past year, BGM or VTVT?
VTVT returned +36.22% over the past 12 months, compared with -96.31% for BGM (price return, excluding dividends). Past performance does not predict future results.
Are BGM Group and vTv Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.